2026 EHA: Phase III frontMIND Study Demonstrates Significant PFS Improvement with Tafasitamab-Based Combination Therapy in First-Line DLBCL

BEIJING

InnoCare Pharma, the Chinese biotech company listed on the Hong Kong Stock Exchange (09969.HK) and the Shanghai Stock Exchange STAR Market (688428.SH), announced on Wednesday that its tafasitamab-based combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in a pivotal Phase III trial for first-line treatment of diffuse large B-cell lymphoma.

The results of the global frontMIND study were presented as an oral report at the plenary session—the highest-ranking session—of the 2026 European Hematology Association annual congress, underscoring the scientific community's interest in the findings.

Significant Survival Benefit

The frontMIND trial, designated S101, was a randomized, double-blind, placebo-controlled, international multicenter study designed to determine whether a treatment regimen could outperform the current first-line standard of care, R-CHOP, in both efficacy and safety.

After a median follow-up of 35.2 months, the combination of tafasitamab, lenalidomide, and R-CHOP—known as Tafa-Len-R-CHOP—reduced the risk of disease progression or death by 25% compared with R-CHOP alone, yielding a hazard ratio of 0.75 with a P-value of 0.0194, meeting the study's primary endpoint.

The two-year progression-free survival rate improved by 8.2 percentage points in the combination-therapy arm, while the three-year rate rose by 6.6 percentage points.

Consistent Across Subtypes

Pre-specified subgroup analyses showed a consistent progression-free survival benefit across all major patient populations, including those with lymphoma subtypes confirmed by a central laboratory and both cell-of-origin molecular subtypes—activated B-cell type and germinal center B-cell type.

The finding is particularly significant because DLBCL is a heterogeneous disease, and therapies that work across molecular subtypes are rare. High-risk DLBCL and high-grade B-cell lymphoma have long represented an area of substantial unmet medical need, with limited advances in first-line treatment over the past two decades.

Manageable Safety Profile

On safety, the Tafa-Len-R-CHOP regimen was generally well tolerated. Its safety profile was consistent with what would be expected from adding tafasitamab and lenalidomide to the R-CHOP backbone, the company said. Newly observed adverse events were manageable and did not affect the ability to deliver the full R-CHOP regimen as planned.

A Potential New Standard of Care

InnoCare said the data support Tafa-Len-R-CHOP as a potential new first-line standard of care for patients with high-risk DLBCL and high-grade B-cell lymphoma, regardless of cell-of-origin molecular subtype.

If ultimately approved on the strength of these data, the combination could reshape the treatment landscape for one of the most common and aggressive forms of non-Hodgkin lymphoma, a disease that affects roughly 150,000 patients worldwide each year.

About InnoCare

Beijing InnoCare Pharma Tech Co., Ltd. is a commercial-stage biotech company focused on developing innovative therapies for malignant tumors and autoimmune diseases. The company has built an integrated drug-discovery platform and a robust pipeline that includes three approved innovative drugs—ocrelabrutinib, tafasitamab, and zurletrectinib—more than a dozen clinical-stage candidates, and multiple preclinical programs. InnoCare has offices in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.